Background pattern

MEMANTINE RATIOPHARM 20 mg FILM-COATED TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MEMANTINE RATIOPHARM 20 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the Patient

Memantina ratiopharm 20mg film-coated tablets EFG

Memantine hydrochloride

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Memantina ratiopharm and what is it used for
  2. What you need to know before you take Memantina ratiopharm
  3. How to take Memantina ratiopharm
  4. Possible side effects
  5. Storing Memantina ratiopharm
  6. Contents of the pack and other information

1. What is Memantina ratiopharm and what is it used for

How it worksMemantina ratiopharm

Memantina ratiopharm belongs to a group of medicines called anti-dementia medicines.

Memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that are involved in the transmission of important nerve signals in learning and memory. Memantina ratiopharm belongs to a group of medicines called NMDA receptor antagonists. Memantina ratiopharm acts on these receptors, improving the transmission of nerve signals and memory.

What it is used forMemantina ratiopharm

Memantina ratiopharm is used in the treatment of patients with moderate to severe Alzheimer's disease.

2. What you need to know before you take Memantina ratiopharm

Do not takeMemantina ratiopharm:

  • if you are allergic to memantine hydrochloride, peanuts or soy or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to take Memantina ratiopharm:

  • if you have a history of epileptic seizures.
  • if you have recently suffered a myocardial infarction (heart attack), if you suffer from congestive heart failure or if you have uncontrolled hypertension (high blood pressure).

In these situations, treatment should be carefully supervised and your doctor should regularly re-evaluate the clinical benefit of Memantina ratiopharm.

If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.

The use of memantine should be avoided with other medicines such as

  • amantadine (for the treatment of Parkinson's disease),
  • ketamine (a medicine usually used as an anesthetic),
  • dextromethorphan (a medicine for the treatment of cough) and
  • other NMDA antagonists.

Children and adolescents

Memantina ratiopharm is not recommended for use in children and adolescents under 18 years of age.

Other medicines and Memantina ratiopharm

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, the administration of Memantina ratiopharm may produce changes in the effects of the following medicines, so your doctor may need to adjust the dose:

  • amantadine, ketamine, dextromethorphan
  • dantrolene, baclofen
  • cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine
  • hydrochlorothiazide (or any combination with hydrochlorothiazide)
  • anticholinergics (substances usually used to treat movement disorders or intestinal spasms)
  • anticonvulsants (substances used to prevent and eliminate convulsions)
  • barbiturates (substances usually used to induce sleep)
  • dopaminergic agonists (substances such as L-dopa, bromocriptine)
  • neuroleptics (substances used in the treatment of mental illnesses)
  • oral anticoagulants

If you are admitted to hospital, inform your doctor that you are taking Memantina ratiopharm.

Taking Memantina ratiopharm with food and drinks

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from a normal diet to a strict vegetarian diet) or if you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections (urinary tract), as your doctor may need to adjust the dose of the medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Memantine is not recommended for use in pregnant women.

Women taking Memantina ratiopharm should stop breastfeeding.

Driving and using machines

Your doctor will inform you whether your illness allows you to drive and use machines safely.

Also, Memantina ratiopharm may alter your reaction ability, so driving or operating machinery may be inappropriate.

Memantina ratiopharm contains lactose and soy lecithin

This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.

This medicine contains soy lecithin. If you are allergic to peanuts or soy, do not take this medicine.

3. How to take Memantina ratiopharm

Follow exactly the administration instructions of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

Dosage

The recommended dose of Memantina ratiopharm for adults and the elderly is 20 mg once a day.

To reduce the risk of adverse effects, this dose should be achieved gradually following a daily treatment scheme. To adjust the dose, there are tablets with different doses.

At the start of treatment, you will take 5 mg once a day. This dose will be increased weekly by 5 mg until the recommended dose (maintenance dose) is reached. The recommended maintenance dose is 20 mg once a day, which is reached at the beginning of the fourth week.

The tablet can be divided into equal doses.

Dosage for patients with renal insufficiency

If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.

Administration

Memantina ratiopharm should be administered orally once a day. To get the most out of your medication, you should take it every day and at the same time.

The tablets should be swallowed with a little water. The tablets can be taken with or without food.

Duration of treatment

Continue taking Memantina ratiopharm as long as it is beneficial for you. Your doctor should evaluate the effects of your treatment periodically.

If you take more Memantina ratiopharm than you should

  • Generally, taking too much Memantina ratiopharm should not cause you any harm. You may experience an increase in the symptoms described in section 4 "Possible side effects".
  • If you take an overdose of Memantina ratiopharm, contact your doctor or seek medical advice, as you may need medical attention.

If you forget to take Memantina ratiopharm

  • If you realize that you have forgotten to take your dose of Memantina ratiopharm, wait and take the next dose at the usual time.
  • Do not take a double dose to make up for forgotten doses.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Memantina ratiopharm can cause side effects, although not everybody gets them.

Generally, side effects are mild to moderate.

Frequent (affects 1 to 10in every 100patients):

  • Headache, drowsiness, constipation, elevated liver function tests, dizziness, balance disorder, difficult breathing, high blood pressure, and hypersensitivity to the medicine.

Uncommon (affects 1 to 10in every 1,000patients):

  • Fatigue, fungal infections, confusion, hallucinations, vomiting, gait disturbance, heart failure, and formation of blood clots in the venous system (thrombosis/venous thromboembolism).

Rare (affects less than 1in every 10,000patients):

  • Seizures.

Frequency not known (frequency cannot be estimated from the available data):

  • Pancreatitis, hepatitis, and psychotic reactions.

Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Memantina ratiopharm

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister pack after EXP. The expiry date is the last day of the month shown.

Blister packs

Do not store above 25°C.

HDPE bottles

This medicine does not require any special storage conditions.

Shelf-life after first opening of the container: 6 months

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.

6. Contents of the pack and other information

Composition of Memantina ratiopharm

  • The active substance is memantine hydrochloride.

Each tablet contains 20 mg of memantine hydrochloride, equivalent to 16.62 mg of memantine.

  • The other ingredients are:

Core of the tablet

Microcrystalline cellulose (E 460), pregelatinized starch (E 1404), anhydrous lactose, colloidal anhydrous silica (E 551), magnesium stearate (E 470b).

Coating

Polysorbate 80 (E 433), polyvinyl alcohol (E 1203), titanium dioxide (E 171), talc (E 553b), soy lecithin (E 322), xanthan gum (E 415).

Appearance of the product and pack contents

White to off-white, biconvex, capsule-shaped tablets (15.6 x 8.0 mm), with a break line on one side and with the number "20" embossed on the other side.

Memantina ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 56, 98, and 100 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorisation holder

ratiopharm GmbH

Graf-Arco-Straße 3

89079 Ulm

Germany

Manufacturer

Merckle GmbH

Ludwig-Merckle-Straße 3

89143 Blaubeuren

Germany

TEVA Pharmaceutical Works Private Limited Company

Pallagi út 13, 4042 Debrecen

Hungary

HBM Pharma s.r.o.

Slabinská 30, 03680 Martin

Slovakia

You can request more information about this medicine from the local representative of the marketing authorisation holder:

Belgium

Teva Pharma Belgium N.V./S.A./AG

Tel: +32 3 820 73 73

Lithuania

UAB “Sicor Biotech”

Tel: +370 5 266 0203

Bulgaria

???? ????????????? ???????? ????

Tel: +359 2 489 95 82

Luxembourg

ratiopharm GmbH

Germany

Tel: +49 731 402 02

Czech Republic

Teva Pharmaceuticals CR, s.r.o.

Tel: +420 251 007 111

Hungary

Teva Gyógyszergyár Zrt.

Tel: +36 1 288 64 00

Denmark

Teva Denmark A/S

Tel: +45 44 98 55 11

Malta

Teva Pharmaceuticals Ireland

Ireland

Tel: +353 51 321 740

Germany

ratiopharm GmbH

Tel: +49 731 402 02

Netherlands

Teva Nederland B.V.

Tel: +31 800 0228 400

Estonia

UAB “Sicor Biotech” Eesti filiaal

Tel: +372 661 0801

Norway

ratiopharm AS

Tel: +47 66 77 55 90

Greece

Teva Ελλάς Α.Ε.

Tel: +30 210 72 79 099

Austria

ratiopharm Arzneimittel Vertriebs-GmbH

Tel: +43 1 97 007 0

Spain

ratiopharm España, S.A.

Tel: +34 91 567 29 70

Poland

Teva Pharmaceuticals Polska Sp. z o.o.

Tel: +48 22 345 93 00

France

Teva Santé

Tel: +33 1 55 91 78 00

Portugal

ratiopharm, Comércio e Indústria de Produtos Farmacêuticos, Lda

Tel: +351 21 476 75 50

Croatia

Pliva Hrvatska d.o.o

Tel: +385 1 37 20 000

Romania

Teva Pharmaceuticals S.R.L

Tel: +40 21 230 65 24

Ireland

Teva Pharmaceuticals Ireland

Tel: +353 51 321740

Slovenia

Pliva Ljubljana d.o.o.

Tel: +386 1 58 90 390

Iceland

Medical ehf.

Tel: +354 534 3500

Slovakia

TEVA Pharmaceuticals Slovakia s.r.o.

Tel: +421 2 57 26 79 11

Italy

Teva Italia S.r.l.

Tel: +39 02 89 17 98 1

Finland

ratiopharm Oy

Tel: +358 20 180 5900

Cyprus

Teva Ελλάς Α.Ε., Greece

Tel: +30 210 72 79 099

Sweden

Teva Sweden AB

Tel: +46 42 12 11 00

Latvia

UAB “Sicor Biotech” filiale Latvija

Tel: +371 673 23 666

United Kingdom

Teva UK Limited

Tel: +44 1977 628500

Date of last revision of this leaflet:<{MM/AAAA}><{month AAAA}>

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe